NR4A1 and breast cancer: These results show that the 3,5-disubstituted phenyl analogs act as NR4A1 antagonists in breast cancer cells, as previously observed with other 3,5-disubstituted phenyl bis-indoles containing the 4-hydroxyl group [20,21].